What is HC Wainwright’s Estimate for IN8bio FY2029 Earnings?

IN8bio, Inc. (NASDAQ:INAB) – Research analysts at HC Wainwright increased their FY2029 earnings per share estimates for shares of IN8bio in a research report issued on Friday, August 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.32 for the year, up from their prior estimate of $0.27. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($1.53) per share.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.09.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.00.

IN8bio Trading Down 0.3%

NASDAQ:INAB opened at $0.98 on Monday. The company’s 50-day moving average price is $1.32 and its 200-day moving average price is $1.56. The company has a market cap of $9.62 million, a P/E ratio of -0.60 and a beta of 0.24. IN8bio has a twelve month low of $0.90 and a twelve month high of $2.73.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP purchased a new stake in IN8bio in the third quarter valued at $107,000. Citadel Advisors LLC purchased a new position in shares of IN8bio during the 3rd quarter worth $54,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of IN8bio during the 4th quarter worth about $56,000. Franklin Resources Inc. raised its holdings in IN8bio by 381.6% in the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock valued at $2,048,000 after buying an additional 724,637 shares during the period. Finally, HRT Financial LP purchased a new stake in IN8bio in the 4th quarter valued at about $34,000. 92.05% of the stock is currently owned by institutional investors and hedge funds.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.